

In brief

COVID-19 vaccines in Australia

18 March 2022

In brief

- Internationally as of 16 March 2022, [35 vaccines](#) are approved and [11.04 billion](#) doses have been administered.^{1, 2}
- In [Australia](#), four vaccines have been approved for use - Comirnaty (Pfizer), Spikevax (Moderna), Vaxzevria (AstraZeneca), and Nuvaxovid (Novavax). As of 13 March 2022, approximately 55.1 million doses have been administered.³
- All vaccines that are approved for use have strong safety profiles and benefit to risk ratios.⁴
- [Vaxzevria](#), [Comirnaty](#), [Spikevax](#), and [Nuvaxovid](#) vaccines have been shown to:⁵⁻⁸
 - reduce symptomatic disease and mortality⁵⁻⁸
 - reduce the chance of [onward transmission](#) by 40-50%^{9, 10}
 - reduce hospitalisation rates in 'real world' effectiveness studies, Vaxzevria by [80% to 95%](#), Comirnaty by [71% to 97%](#), Spikevax by [95.7% to 98.2%](#), and Nuvaxovid by [100%](#).¹¹⁻¹⁶
- In Australia, the [Therapeutic Goods Administration](#) provides regulatory and safety information on COVID-19 vaccines, monitors the safety of all vaccines approved for use, and publishes a [COVID-19 vaccine safety report](#) weekly.^{17, 18}
- The [Australian Technical Advisory Group on Immunisation](#) advises the Federal Minister for Health on the National Immunisation Program and other immunisation issues. The Australian Technical Advisory Group on Immunisation publishes regular COVID-19 vaccination statements and weekly COVID-19 meeting updates.¹⁹

Latest research evidence

- A [cohort study from England](#) reported that booster vaccination with either Comirnaty or Spikevax vaccine was highly protective against hospitalisation and death in Omicron cases (hazard ratio for hospital admission 8 to 11 weeks post-booster versus unvaccinated was 0.22).²⁰
- An [open-label, non-randomized clinical study](#) found that a fourth dose of either the Comirnaty or the Spikevax vaccine induced IgG antibodies and increased the neutralizing antibody titers, which were higher than those achieved after the third dose. Compared to individuals vaccinated with three doses only, individuals who received a fourth dose had a reduced risk of any SARS-CoV-2 infection (vaccine effectiveness: 30% for Comirnaty; 11% for Spikevax) and symptomatic disease (vaccine effectiveness: 43% for Comirnaty; 31% for Spikevax).²¹
- In [elderly people aged 70 years or over](#) in Finland (pre-print study), a third dose of Comirnaty vaccine increased the vaccine effectiveness against COVID-19-related hospitalisation to 96% before the Omicron period, and to 95% during the Omicron period.²²
- A booster dose induced similar neutralising antibody titers against the [Omicron BA.1 and BA.2](#) subvariants.²³ [Neutralisation titers against the Omicron variant](#) remained detectable six months after Spikevax booster vaccination.²⁴

The Critical Intelligence Unit maintains a living evidence table on [COVID-19 vaccines](#) which was used to inform this brief.²⁵ The living evidence table is updated weekly.

References

1. Our World in Data. Coronavirus (COVID-19) Vaccinations [Internet] United Kingdom: University of Oxford, 2022 Mar 10 [cited 2022 Mar 11]. Available from: <https://ourworldindata.org/covid-vaccinations>.
2. COVID19 vaccine tracker [Internet] Canada: McGill University [cited 2022 Mar 11] Available from: <https://covid19.trackvaccines.org/vaccines/>.
3. Therapeutic Goods Administration. COVID-19 vaccine weekly safety report - 17-03-2022 [Internet]. Australia: Therapeutic Goods Administration, Department of Health, Australian Government; 2022 Mar 17 [cited 2022 Mar 18]. Available from: <https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report-17-03-2022>.
4. Holder J. Tracking Coronavirus Vaccinations Around the World [Internet] United States: The New York Times Company; 2021 Aug 12 [cited 2021 Aug 24]. Available from: <https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html>.
5. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *NEJM*. 2020 2020/12/31;383(27):2603-15. DOI: 10.1056/NEJMoa2034577
6. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet*. 2021;397(10269):99-111. DOI: 10.1016/S0140-6736(20)32661-1
7. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *NEJM*. 2020 2021/02/04;384(5):403-16. DOI: 10.1056/NEJMoa2035389
8. Heath PT, Galiza EP, Baxter DN, et al. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. *NEJM*. 2021 2021/09/23;385(13):1172-83. DOI: 10.1056/NEJMoa2107659
9. Harris RJ, Hall JA, Zaidi A, et al. Effect of Vaccination on Household Transmission of SARS-CoV-2 in England. *NEJM*. 2021:1-2. DOI: 10.1056/NEJMc2107717
10. Shah ASV, Gribben C, Bishop J, et al. Effect of Vaccination on Transmission of SARS-CoV-2. *NEJM*. 2021 2021/10/28;385(18):1718-20. DOI: 10.1056/NEJMc2106757
11. Hyams C, Marlow R, Maseko Z, et al. Assessing the Effectiveness of BNT162b2 and ChAdOx1nCoV-19 COVID-19 Vaccination in Prevention of Hospitalisations in Elderly and Frail Adults: A Single Centre Test Negative Case-Control Study. *Lancet*. 2021.
12. Pramod S, Govindan D, Ramasubramani P, et al. Effectiveness of Covishield vaccine in preventing Covid-19 – A test-negative case-control study. *medRxiv*. 2021:1-11. DOI: 10.1101/2021.07.19.21260693
13. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. *Lancet*. 2021;397(10287):1819-29. DOI: 10.1016/S0140-6736(21)00947-8
14. El Sahly HM, Baden LR, Essink B, et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. *NEJM*. 2021. DOI: 10.1056/NEJMoa2113017
15. Chemaitelly H, Yassine HM, Benslimane FM, et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. *Nat Med*. 2021 2021/09/01;27(9):1614-21. DOI: 10.1038/s41591-021-01446-y
16. Dunkle LM, Kotloff KL, Gay CL, et al. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. *NEJM*. 2021 2022/02/10;386(6):531-43. DOI: 10.1056/NEJMoa2116185
17. Therapeutic Goods Administration (TGA). COVID-19 [Internet]. Canberra, Australia: TGA; 2022 [cited 2022 Mar 18]. Available from: <https://www.tga.gov.au/safety-information/covid-19>.

18. Therapeutic Goods Administration (TGA). COVID-19 vaccine safety monitoring and reporting [Internet]. Canberra, Australia: TGA; 2022 [cited 2022 Mar 18]. Available from: <https://www.tga.gov.au/covid-19-vaccine-safety-monitoring-and-reporting>.
19. Australian Government Department of Health. Australian Technical Advisory Group on Immunisation (ATAGI) [Internet]. Canberra, Australia: Australian Government Department of Health; 2022 [cited 2022 Mar 18]. Available from: <https://www.health.gov.au/committees-and-groups/australian-technical-advisory-group-on-immunisation-atagi>.
20. Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. *Lancet*. 2022. DOI: 10.1016/S0140-6736(22)00462-7
21. Regev-Yochay G, Gonen T, Gilboa M, et al. Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron. *NEJM*. 2022. DOI: 10.1056/NEJMc2202542
22. Baum U, Poukka E, Leino T, et al. High vaccine effectiveness against severe Covid-19 in the elderly in Finland before and after the emergence of Omicron. *medRxiv*. 2022:2022.03.11.22272140. DOI: 10.1101/2022.03.11.22272140
23. Yu J, Collier A-rY, Rowe M, et al. Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants. *NEJM*. 2022. DOI: 10.1056/NEJMc2201849
24. Pajon R, Doria-Rose NA, Shen X, et al. SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. *NEJM*. 2022. DOI: 10.1056/NEJMc2119912
25. Agency for Clinical Innovation. Living Evidence - COVID-19 vaccines [Internet] [Internet]. Australia: Agency for Clinical Innovation; 2022 Mar 08 [cited 2022 Mar 11]. Available from: <https://aci.health.nsw.gov.au/covid-19/critical-intelligence-unit/covid-19-vaccines>.

SHPN: (ACI) 220208 | TRIM: ACI/D21/695-30 | Edition 21